CDKN2A and neoplasm: This choice is justified by the following: (i) the role of class IIa and of their partners in this tumor is well characterized [15, 34, 39] and (ii) mutations in two key elements of the senescent pathway, RB1 and CDKN2A, in LMS are mutually exclusive and strongly associate with patient survival (Fig. S5a-b).